Huntersville, North Carolina 28078


Primary Objective: This is a study to investigate the feasibility of harvesting, expanding in culture, and freezing circulating tumor cells and immune cells from cancer patients and healthy volunteers.


Inclusion Criteria: - Histological diagnosis of metastatic stage IV or locally advanced (unresectable) stage III cancer of any solid tumor type. Patients may have been previously treated or chemo naïve or healthy volunteer - Age > 18yo - Life expectancy > 12 weeks - ECOG Performance Status of 0, 1, 2, or 3 (Appendix 2) - Screening laboratory values must meet the following criteria: - WBC ≥2000/µL - Neutrophils ≥1500/µL - Platelets >100x103/µL - Hemoglobin ≥8 g/dL - Creatinine <2.5 x ULN - AST ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases - Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL) Exclusion Criteria: - Primary Hematologic Malignancies (leukemia, lymphoma) - Patients with any active infection requiring therapy (fever, localizing source) will be excluded until the infection resolves. - History of, or a positive test for HIV-1, HIV-2, or HTLV-1 serum antibody, hepatitis B surface antigen, or hepatitis C positive RNA - Underlying medical condition that, in the Principal Investigator's or treating oncologist's opinion, will obscure the interpretation of the patient's safety.



Primary Contact:

Principal Investigator
John Powderly, M.D.
Carolina BioOncology Institute

John Powderly, M.D.
Phone: 704-947-6599

Backup Contact:


Location Contact:

Huntersville, North Carolina 28078
United States

Amanda Balasco, CCRC
Phone: 704-947-6599

Site Status: Recruiting

Data Source:

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.